US health regulator seeks voluntary action against Dr Reddy’s Duvvada facility

India’s leading pharma company Dr Reddy’s Laboratories said that “The US health regulator has asked the company to take voluntary action against its Duvvada Facility.”

In a filing with BSE, Dr Reddy’s said, “Further to our intimation dated on August 20, 2019. With regard to the audit of our Formulations Manufacturing Plant (Vizag SEZ Plant 1 – FTO 7) at Duvvada, Visakhapatnam.”

“We would like to inform you that we have been notified by the USFDA that the inspection classification of the above-referred facility is determined as Voluntary Action Initiated (VAI),” the filing added.